版本:
中国

BRIEF-Crescita Therapeutics announces agreement with Taro Pharmaceuticals for Pliaglis

April 25 Crescita Therapeutics Inc

* Crescita Therapeutics announces agreement with Taro Pharmaceuticals for Pliaglis

* Crescita Therapeutics - entered development and commercialization license agreement with Taro Pharmaceuticals, unit of Taro Pharmaceutical Industries

* Crescita Therapeutics - under terms of agreement, Crescita has granted Taro exclusive license to rights to sell and distribute Pliaglis in U.S. market

* Crescita Therapeutics Inc - in consideration of rights granted under agreement taro will make an upfront, non-dilutive payment of US$2.0 million to Crescita

* Crescita Therapeutics Inc - under deal Taro will also make up to US$5.75 million in non-dilutive development and sales milestone payments to Crescita

* Crescita Therapeutics Inc - in addition, Crescita and Taro have entered into a fee-for-service development agreement

* Crescita Therapeutics Inc - Crescita retains all rights to Pliaglis in Canada and Mexico

* Crescita Therapeutics Inc - fee-for-service development with Taro wherein co to provide services related to development of Pliaglis and enhanced formulation

* Crescita Therapeutics Inc - co to receive fees related to fee-for service development based on services performed Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐